Mufg Securities Americas Inc. Takes Position in Axon Enterprise, Inc. (NASDAQ:AXON)

Mufg Securities Americas Inc. purchased a new stake in Axon Enterprise, Inc. (NASDAQ:AXON) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 1,070 shares of the biotechnology company’s stock, valued at approximately $636,000.

Other institutional investors have also made changes to their positions in the company. Capital World Investors raised its holdings in Axon Enterprise by 86.4% during the 4th quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company’s stock worth $1,079,145,000 after purchasing an additional 841,772 shares during the last quarter. Alliancebernstein L.P. raised its holdings in Axon Enterprise by 273.8% during the 4th quarter. Alliancebernstein L.P. now owns 1,109,045 shares of the biotechnology company’s stock worth $659,128,000 after purchasing an additional 812,337 shares during the last quarter. Norges Bank bought a new stake in Axon Enterprise during the 4th quarter worth about $482,081,000. GQG Partners LLC bought a new stake in Axon Enterprise during the 4th quarter worth about $478,349,000. Finally, Vanguard Group Inc. raised its holdings in Axon Enterprise by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 8,446,437 shares of the biotechnology company’s stock worth $5,019,886,000 after purchasing an additional 275,959 shares during the last quarter. 79.08% of the stock is owned by institutional investors.

Insider Transactions at Axon Enterprise

In other news, Director Jeri Williams sold 307 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $552.72, for a total transaction of $169,685.04. Following the sale, the director now owns 1,627 shares in the company, valued at $899,275.44. This represents a 15.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Patrick W. Smith sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $540.99, for a total value of $5,409,900.00. Following the sale, the chief executive officer now owns 3,063,982 shares in the company, valued at approximately $1,657,583,622.18. This represents a 0.33% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 23,764 shares of company stock worth $14,856,635 in the last 90 days. Corporate insiders own 4.40% of the company’s stock.

Axon Enterprise Trading Down 0.0%

NASDAQ:AXON opened at $728.39 on Friday. Axon Enterprise, Inc. has a twelve month low of $273.52 and a twelve month high of $732.22. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32. The business has a 50 day moving average price of $580.48 and a two-hundred day moving average price of $591.44. The company has a market cap of $56.71 billion, a P/E ratio of 188.21, a price-to-earnings-growth ratio of 5.17 and a beta of 1.24.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, topping analysts’ consensus estimates of $1.34 by $0.07. Axon Enterprise had a return on equity of 7.50% and a net margin of 15.37%. The firm had revenue of $603.63 million during the quarter, compared to the consensus estimate of $585.67 million. During the same quarter in the prior year, the firm posted $1.15 EPS. The business’s revenue was up 31.3% on a year-over-year basis. As a group, analysts expect that Axon Enterprise, Inc. will post 5.8 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have weighed in on AXON shares. Northcoast Research cut Axon Enterprise from a “buy” rating to a “neutral” rating in a report on Wednesday, February 19th. Needham & Company LLC boosted their price objective on Axon Enterprise from $600.00 to $750.00 and gave the stock a “buy” rating in a report on Thursday, May 8th. Craig Hallum lowered Axon Enterprise from a “buy” rating to a “cautious” rating in a research report on Monday, March 10th. Barclays boosted their target price on Axon Enterprise from $726.00 to $735.00 and gave the stock an “overweight” rating in a research report on Friday, May 9th. Finally, JMP Securities restated an “outperform” rating on shares of Axon Enterprise in a research report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $652.73.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.